BioCentury | Jan 30, 2020
Distillery Therapeutics

Targeted Bcl-XL degrader identified to treat ALL, TNBC and SCLC

...model of T-cell ALL, combining the degrader with a chemotherapy regimen containing vincristine, dexamethasone and asparaginase...
BioCentury | May 14, 2019
Distillery Therapeutics

GSK3A inhibition restores asparaginase sensitivity in resistant ALL, AML

...acute myelogenous leukemia (AML) Cell culture and mouse studies suggest inhibiting GSK3A could help treat asparaginase-resistant...
...with asparaginase, co-treatment with two shRNAs against GSK3A or a tool compound GSK3A inhibitor increased asparaginase-induced...
...four T cell ALL, one B cell ALL and three AML cell lines treated with asparaginase...
BioCentury | Jan 4, 2019
Clinical News

FDA approves Servier's ALL therapy acquired in Shire deal

...treat acute lymphoblastic leukemia in patients ages one month to 21 years old. The pegylated L-asparaginase...
BioCentury | Dec 21, 2018
Company News

FDA approves Servier's ALL therapy acquired in Shire deal

...treat acute lymphoblastic leukemia in patients ages one month to 21 years old. The pegylated L-asparaginase...
BioCentury | Nov 9, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

...was expecting 3Q18 sales of $32.1 million. Sales of acute lymphoblastic leukemia (ALL) therapy Erwinaze/Erwinase asparaginase...
BioCentury | Nov 7, 2018
Company News

Earnings roundup: Alnylam off after first peek at Onpattro sales

...was expecting 3Q18 sales of $32.1 million. Sales of acute lymphoblastic leukemia (ALL) therapy Erwinaze/Erwinase asparaginase...
BioCentury | Jun 29, 2018
Clinical News

Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

...ALL treatment options as the reason for stopping the ALL program of Graspa, which comprises L-asparaginase...
...FDA and EMA provided feedback suggesting there would be "little room left" for a new asparaginase...
...Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP), Lyon, France Product: Graspa eryaspase Business: Cancer Molecular target: NA Description: L-asparaginase...
BioCentury | Jun 25, 2018
Clinical News

Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

...ALL treatment options as the reason for stopping the ALL program of Graspa, which comprises L-asparaginase...
...FDA and EMA provided feedback suggesting there would be "little room left" for a new asparaginase...
BioCentury | Apr 20, 2018
Company News

Servier to gain Shire's cancer business, Oncaspar for $2.4B

...pegylated L-asparaginase and Onivyde is a nanoparticle liposome formulation of irinotecan. Cal-PEG is a pegylated L-asparaginase...
BioCentury | Apr 16, 2018
Company News

Servier to gain Shire's cancer business, Oncaspar for $2.4B

...pegylated L-asparaginase and Onivyde is a nanoparticle liposome formulation of irinotecan. Cal-PEG is a pegylated L-asparaginase...
Items per page:
1 - 10 of 138